Hot in Healthcare 2019
is in the works!



Register now


Hot in Healthcare 2019 will be taking place on Thursday 19 September. Join key players from the medtech, biotech and pharma sector at this all-day Benelux life sciences event in Amsterdam to share knowledge, (re)connect and find out what’s hot in healthcare!

The life sciences and healthcare industry is in flux. With technology and innovation reshaping the boundaries of health and healthcare, how do you remain ahead of the curve? How can you add value and contribute to a healthier system?

Hot in Healthcare 2019 is organized by Baker McKenzie in collaboration with Kempen, HollandBIO and

The first part of our event, Life Sciences Dealmakers, will be organized in collaboration with Kempen. The morning session kicks off with keynote speaker Rudi Pauwels (founder of Tibotec-Virco and Biocartis), and offers the opportunity to schedule 1-on-1s with investors. During workshops with scale-ups, investors, VC firms and industry players (medtech, biotech and pharma), the morning will address the latest topics in today’s and tomorrow’s deal making. Panelists include Geraldine O’Keeffe (Partner at LSP), and be sure not to miss the session with Edwin Moses (former CEO of Oxford Asymmetry and Ablynx) in the Hot Seat.

The afternoon session, Future of Healthcare, will focus on the sustainability of healthcare companies, covering topics such as the impact of artificial intelligence, circularity in healthcare and how to face regulatory challenges. Lucien Engelen will deliver the keynote speech, and panelists include Robert Metzke (Philips’ Global Head of Sustainability) and Mark-Jan Harte (CEO at Aidence). In the legacy of last year’s ‘coalition of the doing,’ we look forward to gathering stakeholders from across the spectrum to inspire and find common ground on how to make healthcare future proof.

Follow our LinkedIn page for all updates, program announcements and the reveal of more exciting speakers in the next few weeks.

Secure your spot at Hot in Healthcare 2019 now and pre-register!
* Please note that pre-registration does not guarantee access to the event, as places are limited. 

Confirmed speakers

Stay tuned as we add more speakers to the line-up!

Lucien Engelen

Keynote speaker

CEO / Fellow Transform.Health / Center for the Edge Deloitte

We are in the midst of a digital transformation across society that brings opportunities and challenges. What used to work isn’t good enough anymore in a world that is increasingly becoming digital.

Through his small company Transform.Health as a vehicle, Lucien operates at the convergence of Innovation & Strategy for executive boards, governments, corporates, and professionals via his role as Edge Fellow for the Deloitte Center for the Edge (Amsterdam, Melbourne and San Francisco), at Exponential Medicine (since 2011) at Singularity University in Silicon Valley, the Netherlands as well as currently in the Nordics.

Rudi Pauwels

Keynote speaker

Founder & President Praesens Foundation (former Tibotec-Virco and Biocartis)

Dr. Rudi Pauwels is a scientist and serial bio-tech entrepreneur (pharmaceuticals & diagnostics).

He started at the Rega Institute (Belgium) where he described in the mid-eighties the first methods to search for anti-HIV drugs. His work led to several new anti-HIV compounds including the discovery in 1988 of the nucleotide class of HIV RT inhibitors (e.g. adefovir, tenofovir) and in 1990 the first description of the NNRTI-class of compounds. He (co)-founded several companies in the field of anti-HIV treatment (Tibotec) and diagnostics (Virco, drug resistance testing). The R&D efforts at Tibotec would lead to three next generation anti-HIV drugs: the protease inhibitor darunavir (PREZISTA™), the NNRTI’s etravirine (INTELENCE™) and rilpivirine (EDURANT™). In 1999, he was the driving force behind the creation of Tibotec-Crucell joint-spin off Galapagos Genomics. He headed for a few years the anti-infective (HIV, HCV, TB) drug discovery efforts of Johnson & Johnson. In 2004 Dr. Pauwels went on a 3-year sabbatical at the Swiss Federal Institute of Technology EPFL to deepen his knowledge in micro- and nanotechnology. Driven by the increasing need for more rapid and easy-to-use diagnostics to enable personalized medicine in closer proximity of the patients, he founded Biocartis in 2007.

After leading the company for nearly a decade, he decided in 2017 to focus again on infectious diseases and technology innovation. Inspired by his experiences in West Africa during the Ebola outbreak, he created the Praesens Foundation that is developing, providing and implementing easy to train and use solutions that contribute to better epidemic preparedness, early warning and rapid response for existing and emerging infectious diseases and medicine in general.

Robert Metzke


Chief of Staff Innovation & Strategy and Head of Sustainability Philips

Robert is an experienced global program and team leader with passion for innovation, strategy, social impact and change leadership.

He currently holds a double role as Head of Sustainability and Chief of Staff Innovation & Strategy at Royal Philips.

As Head of Sustainability, Robert has been driving the company strategy towards innovative, sustainable business models. In particular, Robert and his team are leading the Healthy People, Sustainable Planet program (, which embeds sustainability thinking across all sectors of the company.

In his role as Chief of Staff, he is responsible for initiating and driving strategic initiatives across Innovation, Strategy, Design, IP&S, and Sustainability.

Before joining Philips, Robert worked at McKinsey & Company as consultant where he gained 5 years of experience in strategy and innovation in the high-tech, health-care and public sectors.

Edwin Moses

'Hot seat' interview

Chairman Achilles Therapeutics, Evox Therapeutics and Virion Biotherapeutics

Dr. Edwin Moses is a serial entrepreneur in life science companies. As CEO, he built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over €500M in equity and debt financing.

He ran the sales process for each company generating values of £316M and €3.9Bn respectively. At Ablynx, Edwin ensured that the novel Nanobody technology platform was used to build a broad product pipeline, including Cablivi™ which was recently approved for use in both Europe and the USA. In addition, he helped secure pharmaceutical collaborations with a potential value of >€10Bn. Edwin has expertise in high value service provision to the pharmaceutical industry and in drug discovery and development, with more than 25 years of Board level experience in >15 companies. He is currently Chairman of Achilles Therapeutics, Evox Therapeutics and Virion Biotherapeutics.

Geraldine O'Keeffe


Partner LSP

Geraldine O’Keeffe joined LSP in 2008. She became a Partner of the firm in 2010. Geraldine’s prime focus and responsibility within LSP is to invest in listed securities.

Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. In that position, she researched a wide range of innovative life sciences companies, both in Europe and the US. Geraldine brings strong analytical and investment skills to the LSP team. Before joining the financial community, she worked within the life sciences industry for a number of years, gaining first-hand product development experience in a commercial setting. Prior to working in the industry, she lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a very strong scientific background, including a Bachelor’s degree in Biochemistry and Microbiology from University College Cork and a Master’s degree in Biotechnology from University College Galway. She also conducted post-graduate research, inter alia at the prestigious Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. In addition, Geraldine is also a graduate of The Dublin School of Business.

Mark-Jan Harte


CEO and Co-Founder Aidence

Mark-Jan is CEO and co-founder of Aidence. He began his path to founding Aidence more than 20 years ago after completing a masters in Computer Science at the Technical University Eindhoven. This path then led him to occupy various roles in software including IT architecture in finance, founding and exiting a consumer software company and machine learning consultancy.

Why Mark-Jan is excited about applying AI to the healthcare industry: “AI is fascinating because you can build something that is better at a given task than you are yourself. That allows humanity to bootstrap itself and achieve things that were unimaginable until very recently. In healthcare especially there is a huge opportunity to apply this power for the benefit of all.”

Jan De Kerpel

Moderator (morning session)

Managing Director, Life Sciences & Healthcare Kempen

Jan De Kerpel is a seasoned biotech/healthcare business and finance expert with more than 20 years of combined experience in the fields of drug development, equity and growth financing.

Jan brings a unique blend of business, scientific and financial knowledge to enhance the development of high-growth life science companies. He has a proven track record in successfully identifying investment opportunities to a continuously expanding international investor basis and have been instrumental in raising €Bns in equity financing for numerous European biotech, medtech, diagnostics, health services and pharmaceutical companies.

Prior to Kempen, he was a senior equity analist at KBC Securities responsible for the biotech/healthcare sector in the Benelux. Before turning to the investment banking world, he was an R&D director at Devgen (now Syngenta) and senior scientist at Tibotec-Virco (now JNJ), involved in drug development and project-, team-, and business development. His team-work resulted in several commercial products, not only creating shareholder value, but having a life-saving impact for many people around the world.

Academically: master and PhD in life sciences (KULeuven, Belgium), postgraduate in Business Administration (KULeuven) and an executive MBA (Vlerick Business School), corporate finance classes (KUBrussel).

Michaël Dillen


VP Corporate Development and Chief Legal Officer Mithra Pharmaceuticals

Michaël holds a double position of VP Corporate Development and Chief Legal Officer at Mithra Pharmaceuticals, a biotech company focusing on Women Health.

He has gained a vast experience in healthcare through various corporate and legal positions. Before joining Mithra Michaël worked for Terumo, a Japanese stock listed medtech and pharma company. He initiated his career as a lawyer, where he developed a legal practice focusing on corporate and commercial advisory towards both private and institutional clients in the life sciences industry.

Michaël holds law degrees (LL.M.) in both health law and in business law (University of Antwerp and Queen Mary and Westfield College, University of London), as well as a degree in business (Solvay Business School) and corporate finance (Saïd Business School, University of Oxford) .

Cedric Ververken


CEO Confo Therapeutics

Dr. Cedric Ververken joined Confo Therapeutics as CEO in October 2016 from Ablynx NV where he was Vice President Business Development and played a key role in landmark deals for Ablynx.

Prior to moving to business development he worked through various R&D functions at Ablynx, first as a scientist in the pharmacology group and later as project manager, leading cross-functional project teams from discovery up to clinical studies. He therefore brings over 12 years of R&D and business development experience to valorise Confo Therapeutics’ assets and technology.

Servaas Michielssens


Senior Biotechnology Analyst Candriam

With the CFA charter and a Ph.D. in chemistry Servaas Michielssens has a dual background in finance and science.

He graduated from the Katholieke Universiteit Leuven and obtained his PhD from the same university. He continued his academic career as a researcher at the Max Planck Institute in Germany. In 2016 he joined Candriam as a senior analyst and at present he is co-manager of the Candriam Biotechnology and Oncology Impact strategy with in total over $2 Billion assets under management.

Vincent G. Brichard


Founder Paracrine Biologicals

With a background in oncology and immunology, Dr. Brichard’s work has been focused since 1986 on the appealing project of educating our natural defenses – those that protect us from infectious diseases – to recognize and kill cancer cells.

He holds an M.D., a specialized master’s degree in Internal Medicine and Oncology, and a Ph.D. from Louvain University, Brussels. He further holds an MBA from the Harvard Business School.

Dr. Brichard participated actively in the pioneering work done at the Ludwig Institute for Cancer Research (Brussels Branch), under the leadership of Thierry Boon, where he identified several tumor antigens and started the first trials in humans with MAGE antigens. He spent several years at the Institut Curie (Paris), one of Europe’s best-known cancer centers, where he set up a cancer immunotherapy platform. In 2002 he joined GlaxoSmithKline Biologicals, where he was Senior Vice-President and had responsibility for the Immunotherapeutics Business Unit, which covered a broad, integrated approach to immunotherapy – from bench discovery through clinical development and operations to regulatory and commercial activities. In addition to this position, he served as a member of the Board of Directors at GSK Biologicals (annual sales ca. £ 3.5 bn). Based on his experience, translated by more than 90 primary research publications and reviews, he decided to set up his own consulting firm, ViaNova, aiming to provide support to companies, organizations, institutions and individuals in the fields of immuno-oncology and vaccines. Vincent is Venture Partner with LSP since 2016, active mainly in the LSP 5 and 6 funds. In 2019, Vincent founded Paracrine Biologicals, a company based on the pioneering exosomes technology from A*Star in Singapore for therapeutic uses and is setting up with other industry veterans, biotech founders and fund managers a Seed Fund, with the objective to support actively portfolio companies through a presence on the shopfloor.

Sachin Soni


Co-founder and Fund Manager Third Eye

Sachin is the co-founder and Fund Manager of Third Eye Healthcare Fund. Third Eye is an open ended long-biased long/short global healthcare investment fund.

The Fund’s objective is to generate long-term returns for investors by investing in carefully selected publicly listed healthcare companies. The Fund’s performance should come primarily from long positions, with short positions providing protection in the event of market corrections. The Fund maintains up to 50% exposure to European Healthcare. Prior to incorporating Third Eye in 2016, Sachin worked as Director and Head of the Life Sciences team in the securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European Healthcare and Life Sciences sector and won Extel and StarMine awards for stock picking. He has over fifteen years of experience in life sciences, with an exposure to both private (Venture Capital) as well as public market investments, and has been involved in multiple IPOs and secondary transactions, raising over €1.0bn for various life sciences companies.

Geert-Jan Mulder


Managing Partner Forbion

Geert-Jan Mulder, MD, is a Managing Partner at Forbion, co-founded the fund in 2006 and currently serves on the Board of several Forbion portfolio companies.

In addition, Geert-Jan led the firm’s successful investment in bluebirdbio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA®(dalfampridine) board panel to evaluate a new regulatory endpoint in Multiple Sclerosis; PanGenetics B.V. which sold to Abbott, where he led the Series B financing round; Transave, where supported the company’s clinical development for ARIKAYCE®(liposomal amikacin for inhalation) partly as interim CMO, he also served on the Board of Directors till the merger with Insmed (NASDAQ:INSM) in 2010; and Exosome Diagnostics, the leading liquid biopsy company spun out of MGH, where he led the Series A and C, and a director worked together with management to position the company for its successful acquisition by Bio-Techne (NASDAQ:TECH) in 2018. In addition he is a co-author of several Forbion and Forbion portfolio related scientific publications.
Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan spent two years as resident in OBGYN at the University Medical Center of Utrecht (UMC) and several years in the pharmaceutical industry in clinical development and global medical marketing for both Searle (now Pfizer) and Byk Gulden (now Takeda).

Fiona de Hemptinne


Partner UCB Ventures

“Fiona de Hemptinne joined in March 2018, UCB Ventures, a €150 million strategic corporate venture fund which was set up to invest in innovative, longer term and higher risk opportunities beyond UCB’s current focus areas.

She is a board director at Medifin, a medical Imaging start-up since 2015 and at the financiere de Tubize since 2014. She is on the governors’ body at the London Business School since 2015 and a member of their audit and risk committee.

Fiona joined UCB in 2014 in the development bone team as Bone commercial lead based in Slough and as Head of Europe for the Bone Patient Value Unit built the European country teams to prepare the launch of UCB-Amgen’s anti-sclerostin, EVENITY.

She started her career in 2001 and worked in Business Development for GlaxoSmithKline, Biologicals, in Belgium. In 2002, she moved to the US and worked at McKinsey & Company, based in their New Jersey office, covering healthcare clients in the US and Europe. From 2006 to 2014, she had several leadership roles at Lilly UK, Northern Hub and Europe contributing to the launches, new indications and relaunches of several drugs across different therapeutic areas (Neurology, Cardiovascular, Osteoporosis and Immunology), working with alliance partners (BI, Daiichi Sankyo, J&J and GSK), managing patient support programs and leading changes through patent exclusivities and new models.

Fiona graduated with a MSc. in Management degree at the Solvay Business School (U.L.B) and an MBA from Harvard Business School. She is a Fulbright Scholar and a Recipient of Belgian American Education Foundation (BAEF) scholarship.

She is Belgian, lives in London with her husband and her four children.”

Lieke van Kerkhoven


Co-founder FLOOW2 Healthcare

Starting in 2012, Lieke has been driving the global change towards a circular economy by bringing the innovative concept of sharing to the healthcare sector. She co-founded FLOOW2 Healthcare, the first sharing marketplace for healthcare organizations to share equipment, services, facilities, knowledge and skills within or between organizations.

Lieke has a professional background in healthcare. She studied medicine and has been working in several managerial and organizational positions in healthcare organizations in The Netherlands and abroad for 10 years. She experienced first-hand how much organizations can benefit from sharing their assets, in the first place financially, but certainly also socially and environmentally.

Being involved in the transition to a circular economy from the early beginning she has developed a strong vision on why this is taking place at this moment in time, and how it influences our evolution as humans and the organizations we work in.


Berthold A. Hummel

Moderator (morning session)

Partner Baker McKenzie Munich

Berthold A. Hummel is a partner in the Munich office of Baker McKenzie. Berthold has more than 20 years in-depth industry knowledge in private equity and venture capital from private practice and as a senior legal counsel of a leading international private equity firm. Berthold advises European technology and biotech companies on their successful US-IPOs at NASDAQ and NYSE.

Berthold focuses on M&A, private equity, growth capital, venture capital and equity capital markets transactions in advising strategic clients, institutional investors, financial sponsors, large multi-family offices, management teams and companies backed by financial sponsors and institutional investors. He handles all types of complex corporate and commercial transactions, including cross-border acquisitions, financing rounds, takeovers and capital market matters, as well as corporate restructurings, compliance and corporate commercial matters.

Berthold is consistently recommended by leading independent directories, including Chambers, JUVE and Legal 500 and is described as “dedicated to doing a perfect job, and having a very strong commercial and structural sense” as well as “being pragmatic, focused on the essentials, well organized and always available at a late hour.” Best Lawyers in Germany 2019, published by Handelsblatt, listed him among the leading lawyers in the area of private equity.


09:30 - 10:10

Welcome and registration


Part 1: Life Sciences Dealmakers (in collaboration with Kempen)
10:10 - 10:45

Plenary session I: Keynote by Rudi Pauwels

10:45 - 11:00

Coffee Break


11:00 - 11:45

Break-out 1 : A perfect match: strategically considering licensing and partnerships and what companies look for in deals.

moderated by Hiroshi Sheraton

Panel members:

Andre Hoekema (Galápagos)
Michaël Dillen (Mithra Pharmaceuticals)


Break-out 2 : Hot assets: Insights in public investment strategies of life sciences dealmakers.

moderated by Kempen Securities

Panel members:

Geraldine O’Keeffe (LSP)
Sachin Soni (Third Eye)
Servaas Michielssens (Candriam)


Break-out 3 : It’s term sheet time: How to get the most out of your VC term sheet negotiations.

Moderated by Berthold Hummel

Panel members:

Cedric Ververken (Confo Therapeutics)
Geert-Jan Mulder (Forbion)
Vincent Brichard (Paracrine Biologicals)
Fiona de Hemptinne (UCB Ventures)

11:45 - 12:00

Coffee Break


12:00 - 12:45

Plenary Session II: “The Hot Seat” with Edwin Moses
“From the CEO’s perspective: Building a successful biotech company”

Jan de Kerpel chats with former Ablynx CEO Edwin Moses on the success story of Ablynx under Moses’ reign and the challenges for ambitious biotech companies in today’s healthcare system.

12:45 - 13:30

Lunch Break


Part 2: The Future of Healthcare
13:30 - 14:00

Plenary Session III: Keynote by Lucien Engelen


What’s on the horizon in healthcare? Where are we headed? Influence of AI, data, technology and what that means in practice. For patients, providers and payers. What are the opportunities but also the responsibilities?

14:00 - 14:45

Plenary Session IV: Sustainability: Making your healthcare company future proof

Panel members:

Robert Metzke (Philips)
Lieke van Kerkhoven (FLOOW2 Healthcare)
(Circle Economy)

14:45 - 15:00

Coffee Break


15:00 - 15:45

Break-out 1: Regulatory break-out Pharma / Biotech: “The Hot Seat” with Marisa Papaluca (EMA)

The former Senior Scientific Advisor of the European Medicines Agency (EMA) shares insights on current regulatory challenges
Moderated by Els Janssens


Break-out 2: MedTech break-out: Brace yourself: How to navigate the legal landscape of today’s hottest medtech trends

Panel discussion on how to deal with the legal challenges of managed services, health solutions, digital therapeutics and connected devices

15:45 - 16:00

Coffee Break


16:00 - 16:45

Plenary Session V: The next big thing: Hot trends and hurdles in healthcare AI

Panel members:

Mark-Jan Harte (Aidence)
Lucien Engelen (Transform.Health / Center for the Edge Deloitte)

16:45 - 18:00

Drinks and Canapés



Interested to know what Baker McKenzie can do for you?
Please contact our Senior Manager Client Development
Inez Diepenbach through

Martine van de Laar

Legal Director / Co-Chair Healthcare Industry Group

Baker McKenzie Amsterdam

Connect with Martine on LinkedIn or check out her CV.

Rebecca Kuijpers-Zimmerman

Legal Director

Baker McKenzie Amsterdam

Connect with Rebecca on LinkedIn or check out her CV.

Roel Meers


Baker McKenzie Brussels

Check out Roel’s CV.

Kim Tan


Baker McKenzie Amsterdam

Check out Kim’s CV

Sharon van Norden


Baker McKenzie Amsterdam

Check out Sharon’s CV

Derk Christiaans


Baker McKenzie Amsterdam

Mirjam de Blécourt


Baker McKenzie Amsterdam

Check out Mirjam’s CV.

Jan-Willem Gerritsen


Baker McKenzie Amsterdam

Check out Jan-Willem’s CV.

Els Janssens

Senior Associate

Baker McKenzie Brussels

Check out Els’s CV.

Toggle Menu